{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:19:31Z","timestamp":1787026771075,"version":"build-2736575974"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In view of the high incidence of type 2 diabetes mellitus (T2DM) and the high prevalence of multi-organ complications, as well as the issues that traditional hypoglycemic drugs are prone to causing weight gain and the molecular targets and signaling pathways of classic drugs such as metformin have not been systematically clarified, this study aims to systematically analyze the mechanism of action and clinical value of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and It further clarifies key signaling pathways including adenosine monophosphate-activated protein kinase (AMPK), phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt), cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA), and interleukin-6 (IL-6)\/signal transducer and activator of transcription 3 (STAT3) cytokine pathways, prkviding theoretical support for precision interventions in T2DM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The latest domestic and international multi-omics research data, cell\/animal functional experiment results, and clinical evidence were systematically integrated to analyze the structural modification strategies and glucose concentration-dependent mechanism of action of GLP-1RAs. Emphasis was placed on dissecting their regulatory pathways for insulin\/glucagon secretion, as well as key receptor-related networks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Result<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonist (GIP-1RA), when modified at specific amino acid positions, becomes resistant to dipeptidyl peptidase 4 (DPP-4) degradation. It activates the Gs\/cAMP\/PKA\/exchange protein activated by cAMP (EPAC) signaling axis to promote insulin release in a glucose concentration-dependent manner, while suppressing glucagon secretion through Gi\/cAMP downregulation and insulin synergistic effects. Additionally, it induces transient IL-6 release in monocytes, enhancing adipose tissue brownification and thermogenesis via the IL-6\/STAT3 pathway. This mechanism protects pancreatic \u03b2-cells by preventing apoptosis and promoting proliferation, while improving insulin resistance in adipose, hepatic, and skeletal muscle tissues. The compound also exhibits dual effects of weight loss and hepatoprotective (miRNA-regulated lipid metabolism) and nephroprotective (sodium excretion and anti-inflammatory) actions. Key regulatory targets include AMPK, PI3K-Akt, cAMP-PKA, and IL-6\/STAT3.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RAs overcome the limitations of endogenous GLP-1 and traditional hypoglycemic drugs, providing a new strategy for the comprehensive treatment of T2DM featuring \u201chypoglycemia-organ protection-weight loss\u201d. The mechanisms and pathway networks analyzed in this study lay a foundation for the precise intervention of T2DM and rational clinical drug use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2025.1729904","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:54Z","timestamp":1767768714000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Research progress on oral glucagon-like peptide-1 receptor agonists in the treatment of diabetes mellitus type 2"],"prefix":"10.3389","volume":"12","author":[{"given":"Qian","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/j.1463-1326.2008.00853.x","article-title":"GLP\u20101, physiological effects and potential therapeutic applications","volume":"10","author":"Aaboe","year":"2008","journal-title":"Diabetes, Obesity Metabolism"},{"key":"B2","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Advances Endocrinology Metabolism"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.clnu.2024.06.034","article-title":"Metabolic effects of very-low calorie diet, semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus","volume":"43","author":"Anyiam","year":"2024","journal-title":"Clin. Nutr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1096\/fasebj.8.6.8168694","article-title":"Activation\/deactivation of renal Na+, K+\u2010ATPase, a final common pathway for regulation of natriuresis","volume":"8","author":"Aperia","year":"1994","journal-title":"FASEB Journal"},{"key":"B5","volume-title":"Identifying alterations in adipose tissue-derived islet GPCR peptide ligand mRNAs in obesity, implications for islet function","author":"Ashik","year":"2023"},{"key":"B6","article-title":"Type 2 diabetes mellitus (T2DM) accounts for more than 90% of all diabetes cases, while its mechanism is centered on insulin resistance and progressive pancreatic beta-cell dysfunction","author":"Author anonymous","year":"2017"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins, GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2213-8587(15)00462-3","article-title":"Future glucose-lowering drugs for type 2 diabetes","volume":"4","author":"Bailey","year":"2016","journal-title":"Lancet Diabetes and Endocrinology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"20160051","DOI":"10.1515\/hmbci-2016-0051","article-title":"Browning of white adipose tissue: lessons from experimental models","volume":"31","author":"Bargut","year":"2017","journal-title":"Hormone Molecular Biology Clinical Investigation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/10606820213687","article-title":"Structure-function of the glucagon receptor family of G protein-coupled receptors, the glucagon, GIP, GLP-1, and GLP-2 receptors","volume":"8","author":"Brubaker","year":"2002","journal-title":"Recept. Channels"},{"key":"B11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1753-0407.13252","article-title":"Targeting the PI3K\/Akt signaling pathway in pancreatic \u03b2\u2010cells to enhance their survival and function, an emerging therapeutic strategy for type 1 diabetes","volume":"14","author":"Camaya","year":"2022","journal-title":"J. Diabetes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/dom.12959","article-title":"Allosteric modulation as a unifying mechanism for receptor function and regulation","volume":"166","author":"Changeux","year":"2016","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/fendo.2017.00006","article-title":"Clinical review of antidiabetic drugs, implications for type 2 diabetes mellitus management","volume":"8","author":"Chaudhury","year":"2017","journal-title":"Front. Endocrinology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.JAA.0000669456.13763.bd","article-title":"Long-acting GLP-1 receptor agonists: an overview of efficacy, safety, and their role in type 2 diabetes management","volume":"33","author":"Chun","year":"2020","journal-title":"JAAPA"},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1476-5381.2011.01687.x","article-title":"The structure and function of the glucagon\u2010like peptide\u20101 receptor and its ligands","volume":"166","author":"Donnelly","year":"2012","journal-title":"Br. Journal Pharmacology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol. Metabolism"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.3390\/ijms22041509","article-title":"The role of oxidative stress in pancreatic \u03b2 cell dysfunction in diabetes","volume":"22","author":"Eguchi","year":"2021","journal-title":"Int. Journal Molecular Sciences"},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes, a systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-020-0355-7","article-title":"Pancreatic \u03b2-cells in type 1 and type 2 diabetes mellitus, different pathways to failure","volume":"16","author":"Eizirik","year":"2020","journal-title":"Nat. Reviews Endocrinology"},{"key":"B20","article-title":"Development of a liver-pancreas in vitro model using microfluidic organ-on-chip technologies[D]","author":"Essaouiba","year":"2020","journal-title":"Univ. Technol. compi\u00e8gne"},{"key":"B21","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/ajg.2013.24","article-title":"Food and symptom generation in functional gastrointestinal disorders, physiological aspects","volume":"108","author":"Farr\u00e9","year":"2013","journal-title":"Official Journal American College Gastroenterology| ACG"},{"key":"B22","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","article-title":"Pathophysiology of type 2 diabetes mellitus","volume":"21","author":"Galicia-Garcia","year":"2020","journal-title":"Int. Journal Molecular Sciences"},{"key":"B23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3390\/ph16020212","article-title":"Pharmacological treatments and natural biocompounds in weight management","volume":"16","author":"Gasmi","year":"2023","journal-title":"Pharm. (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.7150\/thno.86831","article-title":"Targeting redox imbalance in neurodegeneration, characterizing the role of GLP-1 receptor agonists","volume":"13","author":"Ghosh","year":"2023","journal-title":"Theranostics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12933-023-01798-4","article-title":"Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)","volume":"22","author":"Gourdy","year":"2023","journal-title":"Cardiovasc. Diabetology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3389\/fnins.2019.01112","article-title":"Glucagon-like peptide-1, a focus on neurodegenerative diseases","volume":"13","author":"Grieco","year":"2019","journal-title":"Front. Neuroscience"},{"key":"B27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.dsx.2008.04.005","article-title":"Burden of non-communicable disease, global overview","volume":"4","author":"Habib","year":"2010","journal-title":"Diabetes and Metabolic Syndrome, Clin. Res. and Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"598","DOI":"10.4239\/wjd.v6.i4.598","article-title":"Type 2 diabetes mellitus, from a metabolic disorder to an inflammatory condition","volume":"6","author":"Hameed","year":"2015","journal-title":"World Journal Diabetes"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1483792","DOI":"10.3389\/fphar.2024.1483792","article-title":"Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus","volume":"15","author":"He","year":"2025","journal-title":"Front. Pharmacology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1152\/physrev.1980.60.2.442","article-title":"Mechanism of glucose-induced insulin secretion","volume":"60","author":"Hedeskov","year":"1980","journal-title":"Physiol. Reviews"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.2337\/diabetes.49.11.1751","article-title":"Triggering and amplifying pathways of regulation of insulin secretion by glucose","volume":"49","author":"Henquin","year":"2000","journal-title":"Diabetes"},{"key":"B32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0945-053x(01)00191-3","article-title":"Domain structure and organisation in extracellular matrix proteins","volume":"21","author":"Hohenester","year":"2002","journal-title":"Matrix Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S0083-6729(08)00616-X","article-title":"Insulin granule biogenesis, trafficking and exocytosis","volume":"80","author":"Hou","year":"2009","journal-title":"Vitam. Horm."},{"key":"B34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1177\/87551225221137493","article-title":"Evaluating weight loss with semaglutide in elderly patients with type II diabetes","volume":"39","author":"Huynh","year":"2023","journal-title":"J. Pharm. Technol."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13772","article-title":"News and views July 2019. Diabetes","volume":"21","author":"Idris","year":"2019","journal-title":"Obes. and Metabolism"},{"key":"B36","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41574-019-0254-y","article-title":"The heterogeneous pathogenesis of type 1 diabetes mellitus","volume":"15","author":"Ilonen","year":"2019","journal-title":"Nat. Reviews Endocrinology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S2468-1253(24)00188-2","article-title":"Gastrointestinal effects of GLP-1 receptor agonists, mechanisms, management, and future directions","volume":"9","author":"Jalleh","year":"2024","journal-title":"Lancet Gastroenterology and Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1038\/ijo.2008.247","article-title":"WHO recognition of the global obesity epidemic","volume":"32","author":"James","year":"2008","journal-title":"Int. J. Obes. (Lond)."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41467-018-03941-2","article-title":"Targeting GLP-1 receptor trafficking to improve agonist efficacy","volume":"9","author":"Jones","year":"2018","journal-title":"Nat. Communications"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.16","article-title":"Type 1 diabetes mellitus","volume":"3","author":"Katsarou","year":"2017","journal-title":"Nat. Reviews Disease Primers"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.3748\/wjg.15.4137","article-title":"Problems associated with glucose toxicity, role of hyperglycemia-induced oxidative stress","volume":"15","author":"Kawahito","year":"2009","journal-title":"World Journal Gastroenterology, WJG"},{"key":"B42","doi-asserted-by":"publisher","first-page":"240303","DOI":"10.1098\/rsob.240303","article-title":"GLP-1\/GLP-1R axis: from metabolism (obesity and T2DM) to immunity","volume":"15","author":"Kumar","year":"2025","journal-title":"Open Biol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cmet.2024.09.009","article-title":"Non-invasive lipid panel of MASLD fibrosis transition underscores the role of lipoprotein sulfatides in hepatic immunomodulation","volume":"37","author":"Lam","year":"2025","journal-title":"Cell Metab."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1046\/j.1432-1327.1999.00043.x","article-title":"Molecular mechanisms and regulation of insulin exocytosis as a paradigm of endocrine secretion","volume":"259","author":"Lang","year":"1999","journal-title":"Eur. Journal Biochemistry"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3390\/healthcare13121396","article-title":"Chronic illnesses, varied health patterns and mental health challenges[C]","volume":"13","author":"Leite","year":"2025","journal-title":"Healthcare"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.2337\/db06-s020","article-title":"Glucagon-like peptide 1 secretion by the L-cell, the view from within","volume":"55","author":"Lim","year":"2006","journal-title":"Diabetes"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/1573399812666151016101622","article-title":"Chronic complications of diabetes mellitus, a mini review","volume":"13","author":"Lotfy","year":"2017","journal-title":"Curr. Diabetes Reviews"},{"key":"B49","doi-asserted-by":"publisher","first-page":"7239","DOI":"10.3390\/ijms26157239","article-title":"Glucagon-like peptide-1 receptor (GLP-1R) signaling, making the case for a functionally gs protein-selective GPCR","volume":"26","author":"Lymperopoulos","year":"2025","journal-title":"Int. Journal Molecular Sciences"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.7150\/ijbs.59965","article-title":"GLP-1 receptor agonists (GLP-1RAs), cardiovascular actions and therapeutic potential","volume":"17","author":"Ma","year":"2021","journal-title":"Int. Journal Biological Sciences"},{"key":"B51","doi-asserted-by":"publisher","first-page":"11497","DOI":"10.1074\/jbc.M110856200","article-title":"Differential signaling of cyclic AMP, opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation","volume":"277","author":"Mei","year":"2002","journal-title":"J. Biological Chemistry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.amjmed.2024.09.019","article-title":"Vitamin K antagonist anticoagulation in antiphospholipid syndrome, time in therapeutic range and clinical outcomes","volume":"138","author":"Meir","year":"2025","journal-title":"Am. Journal Medicine"},{"key":"B53","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1463-1326.2012.01663.x","article-title":"GLP-1 receptor activated insulin secretion from pancreatic \u03b2-cells, mechanism and glucose dependence","volume":"15","author":"Meloni","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am. Journal Medicine"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.3390\/cells11132023","article-title":"GLP-1 receptor agonists in neurodegeneration, neurovascular unit in the spotlight","volume":"11","author":"Monti","year":"2022","journal-title":"Cells"},{"key":"B56","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fphar.2018.01566","article-title":"Potential nexus of non-alcoholic fatty liver disease and type 2 diabetes mellitus: insulin resistance between hepatic and peripheral tissues","volume":"9","author":"Mu","year":"2019","journal-title":"Front. Pharmacology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Reviews"},{"key":"B58","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-022-01604-7","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 status 2022","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3390\/ijms24021703","article-title":"GLP-1 receptor agonists in non-alcoholic fatty liver disease, current evidence and future perspectives","volume":"24","author":"Nevola","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"B60","volume-title":"Unacylated ghrelin stimulates fatty acid oxidation in isolated skeletal muscle from rats receiving high-intensity exercise, regardless of dietary fat intake[D]","author":"Notaro","year":"2024"},{"key":"B61","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","article-title":"Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain","volume":"347","author":"Owen","year":"2000","journal-title":"Biochem. J."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1111\/bph.12313","article-title":"Molecular mechanisms underlying physiological and receptor pleiotropic effects mediated by GLP\u20101R activation","volume":"171","author":"Pabreja","year":"2014","journal-title":"Br. Journal Pharmacology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.3390\/cimb45060288","article-title":"The role of GLP1-RAs in direct modulation of lipid metabolism in hepatic tissue as determined using in vitro models of NAFLD","volume":"45","author":"Petrovic","year":"2023","journal-title":"Curr. Issues Molecular Biology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.7326\/M17-0939","article-title":"Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus, a guidance statement update from the American college of physicians","volume":"168","author":"Qaseem","year":"2018","journal-title":"Ann. Internal Medicine"},{"key":"B65","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1677\/JOE-08-0290","article-title":"Physiology of the pancreatic \u03b1-cell and glucagon secretion, role in glucose homeostasis and diabetes","volume":"199","author":"Quesada","year":"2008","journal-title":"J. Endocrinology"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.2337\/db09-1505","article-title":"Membrane potential-dependent inactivation of voltage-gated ion channels in \u03b1-cells inhibits glucagon secretion from human islets","volume":"59","author":"Ramracheya","year":"2010","journal-title":"Diabetes"},{"key":"B67","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40779-022-00410-2","article-title":"DPP-4 inhibitors and GLP-1RAs, cardiovascular safety and benefits","volume":"9","author":"Razavi","year":"2022","journal-title":"Mil. Med. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-025-09807-0","article-title":"Efficacy and safety of GLP-1 agonists in the treatment of T2DM, A systematic review and network meta-analysis","volume":"15","author":"Ren","year":"2025","journal-title":"Sci. Rep."},{"key":"B69","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/pl00008445","article-title":"Plasma levels of interleukin-6 and interleukin-10 in preterm neonates evaluated for sepsis","volume":"160","author":"Romagnoli","year":"2001","journal-title":"Eur. Journal Pediatrics"},{"key":"B70","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1152\/physrev.00013.2014","article-title":"Physiology of proglucagon peptides, role of glucagon and GLP-1 in health and disease","volume":"95","author":"Sandoval","year":"2015","journal-title":"Physiol. Reviews"},{"key":"B71","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc. Diabetology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/ijms19010261","article-title":"The role of miRNAs in the pathophysiology of liver diseases and toxicity","volume":"19","author":"Schueller","year":"2018","journal-title":"Int. Journal Molecular Sciences"},{"key":"B73","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1463-1326.2009.01108.x","article-title":"Roles of cAMP signalling in insulin granule exocytosis","volume":"11","author":"Seino","year":"2009","journal-title":"Diabetes, Obesity Metabolism"},{"key":"B74","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.beem.2006.09.007","article-title":"Pathophysiology of insulin resistance","volume":"20","author":"Sesti","year":"2006","journal-title":"Best Practice and Research Clin. Endocrinology and Metabolism"},{"key":"B75","doi-asserted-by":"publisher","first-page":"171179","DOI":"10.1016\/j.peptides.2024.171179","article-title":"GLP1R and GIPR expression and signaling in pancreatic alpha cells, beta cells and delta cells","volume":"175","author":"Shilleh","year":"2024","journal-title":"Peptides"},{"key":"B76","doi-asserted-by":"publisher","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Research Clinical Practice"},{"key":"B77","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.12993","article-title":"cAMP signalling in insulin and glucagon secretion","volume":"19","author":"Tengholm","year":"2017","journal-title":"Diabetes Obes. Metabolism"},{"key":"B78","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14656566.2021.1999413","article-title":"The role of sulfonylureas in the treatment of type 2 diabetes","volume":"23","author":"Tomlinson","year":"2022","journal-title":"Expert Opinion Pharmacotherapy"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.cmet.2025.06.009","article-title":"Localized GLP1 receptor pre-internalization directs pancreatic alpha cell to beta cell communication","volume":"37","author":"Tong","year":"2025","journal-title":"Cell Metab."},{"key":"B80","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/dom.13921","article-title":"Risk of cardiovascular events in patients with hypertriglyceridaemia, A review of real\u2010world evidence","volume":"22","author":"Toth","year":"2020","journal-title":"Diabetes, Obesity Metabolism"},{"key":"B81","doi-asserted-by":"publisher","first-page":"100169","DOI":"10.1016\/j.etdah.2024.100169","article-title":"Made in China, the international supply of illicit semaglutide and weight-loss medicines online","volume":"5","author":"Turnock","year":"2025","journal-title":"Emerg. Trends Drugs, Addictions, Health"},{"key":"B82","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s12325-019-01101-6","article-title":"Subcutaneous injection of drugs: literature review of factors influencing pain sensation at the injection site","volume":"36","author":"Usach","year":"2019","journal-title":"Adv. Therapy"},{"key":"B83","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia, the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.60082\/2817-5069.1036","article-title":"Arbitrator behaviour in asymmetrical adjudication: an empirical study of investment treaty arbitration","volume":"50","author":"Van Harten","year":"2012","journal-title":"Osgoode Hall. LJ"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e3654","DOI":"10.1002\/dmrr.3654","article-title":"Definitions and criteria for diabetes\u2010related foot disease (IWGDF 2023 update)","volume":"40","author":"Van Netten","year":"2024","journal-title":"Diabetes\/metabolism Research Reviews"},{"key":"B86","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12933-022-01686-3","article-title":"Protection against stroke with glucagon-like peptide-1 receptor agonists, a comprehensive review of potential mechanisms","volume":"21","author":"Verg\u00e8s","year":"2022","journal-title":"Cardiovasc. Diabetology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1210\/10.1210\/er.2006-0038","article-title":"\u03b2-cell failure in diabetes and preservation by clinical treatment","volume":"28","author":"Wajchenberg","year":"2007","journal-title":"Endocr. Reviews"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1930261","DOI":"10.1155\/2017\/1930261","article-title":"Oxidative stress in pancreatic beta cell regeneration","volume":"2017","author":"Wang","year":"2017","journal-title":"Oxidative Medicine Cellular Longevity"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP\u2212 1 receptor agonists for the treatment of obesity: role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinology"},{"key":"B90","doi-asserted-by":"publisher","first-page":"590","DOI":"10.2337\/diabetes.55.03.06.db05-0001","article-title":"Dynamics of glucose-induced localization of PKC isoenzymes in pancreatic \u03b2-cells, diabetes-related changes in the GK rat","volume":"55","author":"Warwar","year":"2006","journal-title":"Diabetes"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.2147\/DMSO.S312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes, Metabolic Syndrome Obesity"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.2217\/bmm-2016-0090","article-title":"The biology of glucagon and the consequences of hyperglucagonemia","volume":"10","author":"Wewer Albrechtsen","year":"2016","journal-title":"Biomarkers Medicine"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1111\/dom.15104","article-title":"Bile acid metabolites in early pregnancy and risk of gestational diabetes mellitus, results from a prospective cohort study","volume":"25","author":"Wu","year":"2023","journal-title":"Diabetes, Obesity Metabolism"},{"key":"B94","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","article-title":"Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced Obese mice","volume":"58","author":"Xu","year":"2009","journal-title":"Diabetes"},{"key":"B95","doi-asserted-by":"publisher","first-page":"4149","DOI":"10.1007\/s00018-014-1680-6","article-title":"Ionic mechanisms in pancreatic \u03b2 cell signaling","volume":"71","author":"Yang","year":"2014","journal-title":"Cell. Molecular Life Sciences"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"B97","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.immuni.2020.12.001","article-title":"The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells","volume":"54","author":"Yousif","year":"2021","journal-title":"Immunity"},{"key":"B98","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/postgradmedj-2015-133281","article-title":"Pathophysiology of type 1 and type 2 diabetes mellitus, a 90-year perspective","volume":"92","author":"Zaccardi","year":"2016","journal-title":"Postgrad. Medical Journal"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1186\/s12889-024-18994-w","article-title":"A qualitative study on inner experience of self-management behavior among elderly patients with type 2 diabetes in rural areas","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Public Health"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1080\/10408398.2022.2120454","article-title":"Food-derived dipeptidyl peptidase IV inhibitory peptides, production, identification, structure-activity relationship, and their potential role in glycemic regulation","volume":"64","author":"Zhang","year":"2024","journal-title":"Crit. Reviews Food Science Nutrition"},{"key":"B101","first-page":"1","article-title":"Localized GLP1 receptor pre-internalization directs asynchronous insulin and glucagon secretion. Cell metabolism","volume":"37","author":"Zhang","year":"2025"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10557-025-07670-9","article-title":"Therapeutic potential of GLP-1 receptor agonists in diabetes and cardiovascular disease: mechanisms and clinical implications","author":"Zhang","year":"2025","journal-title":"Cardiovasc. Drugs Therapy"},{"key":"B103","doi-asserted-by":"publisher","first-page":"15119","DOI":"10.1074\/jbc.M116.726620","article-title":"Differential requirement of the extracellular domain in activation of class BG protein-coupled receptors","volume":"291","author":"Zhao","year":"2016","journal-title":"J. Biological Chemistry"},{"key":"B104","doi-asserted-by":"publisher","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists, beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Endocrinology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor, mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduction Targeted Therapy"},{"key":"B106","first-page":"234","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling: implications for drug design","volume":"46","author":"Zheng","year":"2025","journal-title":"Trends Pharmacological Sciences"},{"key":"B107","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.tips.2025.03.003","article-title":"Structural pharmacology and mechanisms of GLP-1R signaling","volume":"46","author":"Zhou","year":"2025","journal-title":"Trends Pharmacological Sciences"},{"key":"B108","doi-asserted-by":"publisher","first-page":"146141","DOI":"10.1016\/j.ijbiomac.2025.146141","article-title":"Understanding the activation mechanism of GLP-1R\/GIPR by dual agonist tirzepatide via molecular dynamics and protein-peptide binding","volume":"321","author":"Zou","year":"2025","journal-title":"Int. Journal Biological Macromolecules"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1729904\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T06:51:56Z","timestamp":1767768716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2025.1729904\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":108,"alternative-id":["10.3389\/fmolb.2025.1729904"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2025.1729904","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"article-number":"1729904"}}